US · OMCL
Omnicell, Inc.
- Sector
- Healthcare · Medical - Healthcare Information Services
- Headquarters
- Mountain View, CA 94043
- Website
- omnicell.com
Price · as of 2025-12-31
$42.80
Market cap 1.89B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $54.74 | +27.9% |
| Intrinsic Value(DCF) | $17.83 | -58.34% |
| Graham-Dodd Method(GD) | $10.97 | -74.37% |
| Graham Formula(GF) | $0.65 | -98.49% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $14.79 | $42.26 | $4.97 | $9.25 | $5.67 |
| 2012 | $18.96 | $44.34 | $32.68 | $8.26 | $16.85 |
| 2013 | $28.97 | $50.57 | $81.56 | $10.27 | $19.61 |
| 2014 | $31.72 | $53.50 | $123.45 | $11.78 | $19.90 |
| 2015 | $28.48 | $58.58 | $40.00 | $11.39 | $15.18 |
| 2016 | $37.15 | $50.58 | $328.50 | $2.96 | $0.82 |
| 2017 | $44.40 | $107.25 | $84.20 | $7.54 | $6.26 |
| 2018 | $83.35 | $77.81 | $70.65 | $13.57 | $17.01 |
| 2019 | $82.96 | $80.47 | $23.48 | $19.67 | $31.84 |
| 2020 | $135.18 | $105.56 | $7.52 | $14.78 | $5.71 |
| 2021 | $134.80 | $114.07 | $42.87 | $18.33 | $60.46 |
| 2022 | $51.51 | $79.40 | $2.10 | $9.55 | $2.79 |
| 2023 | $28.55 | $54.19 | $0.76 | $7.77 | $1.25 |
| 2024 | $36.99 | $48.79 | $5.67 | $12.41 | $1.43 |
| 2025 | $41.25 | $54.74 | $2.24 | $10.97 | $0.65 |
AI valuation
Our deep-learning model estimates Omnicell, Inc.'s (OMCL) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $54.74
- Current price
- $42.80
- AI upside
- +27.9%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$17.83
-58.34% upside
Graham-Dodd
$10.97
-74.37% upside
Graham Formula
$0.65
-98.49% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| OMCL | Omnicell, Inc. | $42.80 | 1.89B | +28% | -58% | -74% | -98% | 924.00 | 1.54 | 1.60 | 19.91 | — | 5.86 | 42.49% | 0.44% | 0.17% | 0.17% | 0.17% | 0.10% | 0.18 | 0.84 | 1.43 | 0.87 | 0.21 | -8359.00% | 653.00% | -4256.00% | 4.58% | 0.27 | 6.96% | 0.00% | 0.00% | 4.09% | 371.46 | 22.06 | 1.62 | 2.26 |
| ASTH | Astrana Health, Inc. | $20.33 | 1.02B | +100% | +292,397% | -54% | +135% | 28.06 | 1.97 | 0.69 | 11.15 | — | 7.99 | 13.34% | 4.39% | 2.12% | 7.53% | 7.20% | 4.36% | 0.66 | 2.70 | 1.75 | 1.68 | 1.29 | -3023.00% | 4672.00% | 1126.00% | 3.15% | 0.14 | 5.76% | 0.29% | 8.10% | 0.35% | 17.71 | 35.82 | 0.78 | 3.26 |
| GDRX | GoodRx Holdings, Inc. | $1.87 | 635.85M | +1,396% | -39% | -10% | +8% | 30.91 | 1.25 | 0.97 | 3.10 | 29.70 | 6.35 | 92.77% | 10.98% | 10.37% | 3.73% | 14.18% | 1.79% | 0.10 | 2.05 | 2.61 | 2.02 | -1.10 | 10407.00% | 57.00% | -3234.00% | 9.94% | 0.55 | 12.45% | 0.00% | 0.00% | 65.21% | 6.53 | 7.43 | 0.72 | 0.29 |
| OMDA | Omada Health | $12.28 | 711.11M | — | — | — | — | — | — | — | — | — | — | 60.59% | -25.71% | -27.76% | -57.64% | -270.44% | -28.92% | 0.47 | -9.69 | 2.10 | 1.86 | 1.22 | -2975.00% | 3829.00% | -2776.00% | — | -0.63 | -235.67% | — | 0.00% | — | — | — | — | — |
| PGNY | Progyny, Inc. | $17.69 | 1.53B | +175% | +6% | -48% | -30% | 25.63 | 2.91 | 1.16 | 12.09 | 182.64 | 3.06 | 23.63% | 6.62% | 4.54% | 12.48% | 23.59% | 8.67% | 0.05 | — | 2.73 | 2.62 | -0.88 | 1404.00% | 1040.00% | 1041.00% | 12.78% | 1.04 | 86.52% | 0.00% | 0.00% | 5.44% | 14.24 | 6.33 | 0.94 | 6.66 |
| PHR | Phreesia, Inc. | $12.33 | 743.34M | +427% | +131% | — | — | -23.67 | 5.23 | 3.30 | -51.58 | — | 12.82 | 67.86% | -13.84% | -13.94% | -22.67% | -31.04% | -15.43% | 0.07 | -24.75 | 1.78 | 1.38 | 2.60 | -5936.00% | 1783.00% | -11443.00% | 0.60% | 0.28 | 4.43% | 0.00% | 0.00% | 0.00% | -22.71 | 159.09 | 3.14 | 4.70 |
| SDGR | Schrödinger, Inc. | $12.06 | 888.4M | +184% | -53% | — | — | -8.64 | 2.45 | 3.49 | -6.29 | — | 2.48 | 55.74% | -65.23% | -40.36% | -26.29% | -125.97% | -13.33% | 0.30 | — | 2.75 | 2.53 | 1.26 | -4514.00% | 2329.00% | -10756.00% | 1.40% | 0.07 | 9.40% | 0.00% | 0.00% | 10.29% | -3.63 | 48.66 | 2.37 | 0.41 |
| SSII | SS Innovations Internatio… | $4.76 | 921.64M | +1,445% | +6,162% | — | — | -85.61 | 121.83 | 79.40 | -93.41 | — | 121.83 | 40.93% | -91.90% | -92.74% | -138.00% | -81.31% | -56.44% | 1.35 | -19.50 | 1.29 | 0.36 | -1.00 | -3750.00% | 25120.00% | -3573.00% | -0.62% | -0.45 | -43.55% | 0.00% | 0.00% | 0.00% | -87.33 | -163.04 | 80.26 | 31.74 |
| TDOC | Teladoc Health, Inc. | $5.26 | 933.51M | +398% | -42% | -89% | — | -4.54 | 0.66 | 0.36 | 7.86 | — | -4.67 | 69.50% | -10.39% | -7.92% | -13.93% | -13.11% | -6.28% | 0.74 | -13.34 | 2.77 | 2.41 | 1.68 | -8058.00% | -154.00% | 91.00% | 31.39% | 0.73 | 16.74% | 0.00% | 0.00% | 4.21% | -4.40 | 4.05 | 0.46 | -6.80 |
| TXG | 10x Genomics, Inc. | $23.05 | 2.94B | +141% | -55% | -80% | — | -66.29 | 3.63 | 4.49 | -22.74 | — | 3.96 | 69.05% | -17.25% | -6.77% | -5.78% | -26.72% | -4.44% | 0.20 | — | 4.46 | 3.95 | 2.85 | -7697.00% | 525.00% | -237116.00% | 4.51% | 0.89 | 31.35% | 0.00% | 0.00% | 1.90% | -22.74 | 19.38 | 3.92 | 5.92 |
| UFPT | UFP Technologies, Inc. | $210.58 | 1.62B | -43% | +6% | -65% | +13% | 23.04 | 3.71 | 2.61 | 14.60 | 146.78 | 18.38 | 28.27% | 15.32% | 11.33% | 17.82% | 14.23% | 10.64% | 0.32 | 9.42 | 1.19 | 0.65 | 0.99 | 1570.00% | 1950.00% | 3871.00% | 5.02% | 0.58 | 14.70% | 0.00% | 0.00% | 4.92% | 18.29 | 21.39 | 2.80 | 5.53 |
About Omnicell, Inc.
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.
- CEO
- Randall A. Lipps
- Employees
- 3.62K
- Beta
- 0.77
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($17.83 ÷ $42.80) − 1 = -58.34% (DCF, example).